CATALYSTYahoo Finance • 7h ago
Qiagen shares surge on report of advanced EQT takeover talksYahoo Finance report covering Qiagen N.V. (QGEN) market action, institutional positioning, and fundamental catalysts.
Why QGEN Stock slipped -0.24% Today — RQD Quant Desk Flash
$50.22 -0.24% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $50.32
Qiagen N.V. (QGEN) earns a Roarable Rating of B- (Buy) with 71/100 RQD Confidence. High-quality cash engine (62% profit margin, 8% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
ROARABLE B- • BUY
Cap $10.37B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on QGEN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is QGEN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Qiagen N.V. (NYSE: QGEN) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $50.22 (-0.24% 1D, market cap $10.37B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, QGEN ranks #78 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does QGEN compare to KYMR and RGEN in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), QGEN carries a Roarable B- (71/100 RQD), trailing P/E of 24.4x, gross margin of 62.2%, and ROIC of 8.0%. By comparison, KYMR (Kymera Therapeutics Inc.) holds a D grade (50/100 RQD, P/E 32.7x, ROIC -21.4%, cap $10.19B) and RGEN (Repligen Corporation) posts a C grade (64/100 RQD, P/E N/A, ROIC 2.3%, cap $10.69B). Among the 5-stock peer group, QGEN leads on earnings multiple (24.4x) while KRYS leads on capital efficiency (16.5% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for QGEN?
▼
Per QGEN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001015820), Qiagen N.V. generated $2.09B in revenue (+5.7% YoY), $424.9M in net income, and $453.3M in free cash flow against $6.28B in total assets and $1.65B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $50.32 (+0.20%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 21.7% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 71/100 (B-) historically ranked in the Top 14% of excess returns over the next 90 days (+6.8% avg 90D alpha vs SPY • 68.4% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERBUY • B-
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw B- · Rk B
Each axis scored 0–20
12M PRICE TARGET CONE+5.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for QGEN)Realized 20D OHLCV Swing Band: ±4.2%
Deterministic 5-Pillar Attribution (71/100 Composite)
🔍 WHY QGEN SCORES 71/100 (B-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+16/20 pts (23% of score)
20D Institutional Volume Accumulation (±4.2% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (23% of score)
Altman Z-Score 3.54 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9
▼ #1 Drag / Risk Factor: Cash Engine Quality11/20 pts (-9 pt drag)
Capital intensity & 22.3% operating margin leave 9 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C+$45.44+7.6% Next Q
63
Q2 (-2Q)Grade B-$48.90+2.6% Next Q
66
Q3 (-1Q)Grade B-$50.17+0.1% Next Q
68
CurrentGrade B-$50.22+6.8% Hist 90D α
71
Trajectory: C+ (63) → B- (71)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the QGEN Bull Thesis Could Fail
Even with a 71/100 (B-) score, QGEN faces multiple-compression risk if 24.4x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Broader market pullbacks can still drag down strong stocks in the short run.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 59.7% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($45.41) or 200D SMA ($42.62) invalidates the momentum regime and cuts Target Base ($53.16) toward Bear Floor ($41.18).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $QGEN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “QGEN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why QGEN Stock slipped -0.24% Today — RQD Quant Desk Flash
Qiagen N.V. (QGEN) slipped -0.24% to $50.22, trading at 70% of its 52-week range ($32.53 – $57.82). High-quality cash engine (62% profit margin, 8% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 70% of its 52-week range ($32.53 – $57.82) with RSI-14 at 72.4 (OVERBOUGHT (>70)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±4.2% around $50.22 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable B- (Buy) backed by 62.2% gross margin and $453.3M annual free cash flow.
Live QGEN Headlines & Catalysts
MARKET WIREChartMill • 10h ago
QIAGEN N.V. (NYSE:QGEN) Sets Up for a Technical BreakoutChartMill report covering Qiagen N.V. (QGEN) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 13h ago
Do Options Traders Know Something About Qiagen Stock We Don't?TradingView report covering Qiagen N.V. (QGEN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREGuruFocus • 16h ago
Qiagen NV (QGEN) Stock Up 5.0% and Still Undervalued -- GF Score: 76/100GuruFocus report covering Qiagen N.V. (QGEN) market action, institutional positioning, and fundamental catalysts.
RISK WATCHSeeking Alpha • 19h ago
Qiagen: Unanimous Acceptance Takeover Nears Close (Rating Downgrade)Seeking Alpha report covering Qiagen N.V. (QGEN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe National Law Review • 22h ago
QGEN Stock Alert: Halper Sadeh LLC is Investigating Whether QIAGEThe National Law Review report covering Qiagen N.V. (QGEN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Globe and Mail • 1d ago
Bank of America Builds 5.73% Stake in Qiagen via Shares and DerivativesThe Globe and Mail report covering Qiagen N.V. (QGEN) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
Qiagen (NYSE:QGEN) Stock Forecast & Analyst PredictionsSimply Wall St report covering Qiagen N.V. (QGEN) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 2d ago
Qiagen (QGEN) On Its €9.7b Takeover Deal Still Looks Fully ValuedQiagen (QGEN) is back in focus after agreeing to a €9.7b cash takeover by a consortium led by EQT XI at €46.50 per share, along with suspended 2026 guidance and a possible interim dividend. Qiagen’s share price has climb
MARKET WIREYahoo • 3d ago
Global Human Papillomavirus (HPV) Genotyping Panels Market Report 2026 | Capitalize on NGS, AI and Self-Collection Through 2030 with Roche, Abbott, Thermo Fisher and QIAGENDublin, Oct. 30, 2026 (GLOBE NEWSWIRE) -- "Human Papillomavirus (HPV) Genotyping Panels Market Global Report 2026" has been added to ResearchAndMarkets.com's offering. The global human papillomavirus (HPV) genotyping pan
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (QGEN Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
QGEN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +47.88%▲ ASCENDING CHANNEL
2026-11-02O $50.33H $50.34L $50.22C $50.22VOL 3.55M
RES: $52.61SUP: $42.57SMA50: $45.41SMA200: $42.62
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
QGEN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
18.1%/yr Implied 5Y Growth
vs. +5.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on QGEN today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for QGEN. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for QGEN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (QGEN)
Health Care Rank #78 of 1016
⚔️ KYMR vs QGEN Full Matrix →
1. Head-to-Head Health Care Peer Comparison (QGEN vs. KYMR, RGEN, PCVX, KRYS)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Qiagen N.V. (QGEN) ranks #78 by composite RQD confidence (71/100, grade B-) and #109 by equity capitalization ($10.37B). Within this direct 5-issuer industry benchmark cohort, QGEN leads on earnings valuation at 24.4x trailing P/E, while KRYS leads on capital efficiency and profitability with 16.5% ROIC and — gross margin. KRYS currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with QGEN at 71/100 (B-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| QGEN
ACTIVE
Qiagen N.V. | B- | 71/100 | 24.4x | 62.2% | 8.0% | -0.24% | $10.37B | Benchmark Subject |
| KYMR Kymera Therapeutics Inc. | D | 50/100 | 32.7x | — | -21.4% | +3.29% | $10.19B | /kymr-vs-qgen → |
| RGEN Repligen Corporation | C | 64/100 | — | 88.2% | 2.3% | -6.20% | $10.69B | /rgen-vs-qgen → |
| PCVX Vaxcyte Inc. | D | 49/100 | — | — | -27.6% | -0.93% | $9.85B | /pcvx-vs-qgen → |
| KRYS Krystal Biotech Inc. | B | 72/100 | 46.9x | — | 16.5% | +2.38% | $9.61B | /krys-vs-qgen → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001015820In its most recent audited fiscal period (FY2025, filed 2025-12-31), Qiagen N.V. (QGEN) reported GAAP revenue of $2.09B (+5.7% vs. FY2024 revenue of $1.98B , and +6.3% cumulative change since FY2023) , GAAP net income of $424.9M, operating cash flow of $654.3M, and free cash flow of $453.3M (-10.5% YoY). On the balance sheet, QGEN closed FY2025 with $6.28B in total assets against $1.65B in total debt (Altman Z-Score: 3.54, Piotroski F-Score: 9/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $2.09B | $424.9M | $654.3M | $453.3M | $6.28B | $1.65B |
| FY2024 (FY) | 2024-12-31 | $1.98B | $83.6M | $673.6M | $506.4M | $5.69B | $839.7M |
| FY2023 (FY) | 2023-12-31 | $1.97B | $341.3M | $459.5M | $371.0M | $5.71B | $1.34B |
3. QGEN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs QGEN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Qiagen N.V. (NYSE: QGEN) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $50.22 (-0.24% 1D, market cap $10.37B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, QGEN ranks #78 in composite RQD confidence.
How does QGEN compare to KYMR and RGEN in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), QGEN carries a Roarable B- (71/100 RQD), trailing P/E of 24.4x, gross margin of 62.2%, and ROIC of 8.0%. By comparison, KYMR (Kymera Therapeutics Inc.) holds a D grade (50/100 RQD, P/E 32.7x, ROIC -21.4%, cap $10.19B) and RGEN (Repligen Corporation) posts a C grade (64/100 RQD, P/E N/A, ROIC 2.3%, cap $10.69B). Among the 5-stock peer group, QGEN leads on earnings multiple (24.4x) while KRYS leads on capital efficiency (16.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for QGEN?
Per QGEN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001015820), Qiagen N.V. generated $2.09B in revenue (+5.7% YoY), $424.9M in net income, and $453.3M in free cash flow against $6.28B in total assets and $1.65B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is QGEN trading relative to its 50-day, 200-day, and 52-week technical levels?
QGEN last traded at $50.22 (-0.24% on volume of 4,168,167 shares), positioning the stock +10.59% above its 50-day simple moving average ($45.41) and +17.83% above its 200-day simple moving average ($42.62). Across its 52-week range of $32.53 to $57.82, QGEN sits at the 69.9% percentile with a 14-day RSI of 72.4 (OVERBOUGHT (>70)) and an implied next-earnings move of ±4.2% ($48.11 to $52.33).
QGEN Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is QGEN stock moving today?
Why QGEN Stock slipped -0.24% Today — RQD Quant Desk Flash. High-quality cash engine (62% profit margin, 8% return on capital) with steady institutional support.
ROARABLE RATING BRIEF • RQD 71/100 (B-)
✓ STAGE-C NUMBER FIREWALL VERIFIED
QGEN — Qiagen N.V.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:16:25Z
Roarable Rating Brief: What This Means to a Prospective Investor
The Roarable RQD Score is 71 out of 100, graded B- and labeled "Roarable Buy — Sound Institutional Accumulation," per the Roarable RQD rating. Across its five pillars:
- Fundamental Cash Engine: 11 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of 8% and an FCF yield of 4.37%. Modest returns on capital and a moderate cash yield at the current price are the main limits on this score.
- Whale 13F Flow: 16 / 20. Per the Roarable RQD rating, this pillar captures institutional accumulation and options positioning. It is one of the stronger components, though the underlying 13F holder detail is not available in source data.
- Insider Conviction: 15 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The individual transactions are not itemized in the source data.
- Macro Regime Fit: 13 / 20. Per the Roarable RQD rating, this pillar reflects a Beta of 0.95 and sector sensitivity. A beta near 1.0 implies market-like volatility rather than a defensive or aggressive profile.
- Forensic Balance Sheet: 16 / 20. Per the Roarable RQD rating, this pillar reflects an Altman Z of 3.54, a Piotroski F of 9/9, and Debt/Equity of 0.44. These are the strongest forensic readings in the rating.
For a prospective investor, the rating suggests that balance-sheet quality and institutional/insider flow are the primary supports, while cash-generation efficiency (ROIC of 8%) and macro sensitivity are the weaker links. The stock's trading at $50.34 sits within a 52-week range of $32.53 to $57.82 per the market data, so the position relative to that range is a valuation context point rather than a signal in itself. The recent news flow (see Catalysts) includes a takeover-related item that could dominate near-term price action independent of these pillars. This is an analytical summary, not personalized financial advice.
Snapshot
Business
Qiagen N.V. (QGEN) is a NYSE-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry, per the company profile. Per the SEC financials, the company reported revenue of $2090.0M for FY 2025. Not available in source data for product lines, customer base, or detailed revenue model.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $2090.0M | $465.9M | $424.9M | N/A | $453.3M | $839.0M | $1654.4M |
| FY 2024 | $1978.2M | $97.7M | $83.6M | N/A | $506.4M | $663.6M | $839.7M |
| FY 2023 | $1965.3M | $409.9M | $341.3M | N/A | $371.0M | N/A | $1335.1M |
Per the market data, gross margin is 62.2%, operating margin 22.3%, and net margin 20.3%, with ROIC of 8%. Per the Roarable RQD rating, the Altman Z-Score is 3.54 and the Piotroski F-Score is 9/9. Debt/Equity is 0.44 per the Roarable RQD rating. Debt rose from $839.7M in FY 2024 to $1654.4M in FY 2025 per the SEC financials, while cash rose from $663.6M to $839.0M over the same period.
Recent Catalysts & News Wire Analysis
- GREEN / CATALYST: "Qiagen shares surge on report of advanced EQT takeover talks" (Yahoo Finance, 1h ago per the news feed).
- YELLOW / MARKET WIRE: Technical breakout setup (ChartMill); options positioning commentary (TradingView); GF Score of 76/100 with a 5.0% price move (GuruFocus).
- RED / RISK WATCH: "Qiagen: Unanimous Acceptance Takeover Nears Close (Rating Downgrade)" (Seeking Alpha, 12h ago per the news feed). This item carries a downgrade and a deal-closing framing.
- YELLOW / MARKET WIRE: Halper Sadeh LLC investigation item (The National Law Review).
Per the Butterfly Supply-Chain Graph, supply_chain is listed as NONE, with no butterfly links and no proprietary signals. Not available in source data for additional supply-chain signal.
Open Questions
- What are the terms, status, and parties of the takeover talks referenced in the catalyst headlines, and does the "Unanimous Acceptance" item refer to the same transaction?
- What drove the increase in debt from $839.7M to $1654.4M between FY 2024 and FY 2025, and how is it being serviced?
- What are the EPS figures, since the reported EPS values are N/A across all periods?
- Who are the institutional and insider holders behind the Whale and Insider pillar scores?
- What is the nature of the Halper Sadeh LLC investigation referenced in the news feed?
QGEN Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Qiagen N.V. (QGEN) • Click "Debate This Headline" to argue it in the Roar Pit below
🟢 CATALYST Yahoo Finance • 7h ago
Qiagen shares surge on report of advanced EQT takeover talks Yahoo Finance report covering Qiagen N.V. (QGEN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE ChartMill • 10h ago
QIAGEN N.V. (NYSE:QGEN) Sets Up for a Technical Breakout ChartMill report covering Qiagen N.V. (QGEN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 13h ago
Do Options Traders Know Something About Qiagen Stock We Don't? TradingView report covering Qiagen N.V. (QGEN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GuruFocus • 16h ago
Qiagen NV (QGEN) Stock Up 5.0% and Still Undervalued -- GF Score: 76/100 GuruFocus report covering Qiagen N.V. (QGEN) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Seeking Alpha • 19h ago
Qiagen: Unanimous Acceptance Takeover Nears Close (Rating Downgrade) Seeking Alpha report covering Qiagen N.V. (QGEN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The National Law Review • 22h ago
QGEN Stock Alert: Halper Sadeh LLC is Investigating Whether QIAGE The National Law Review report covering Qiagen N.V. (QGEN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Globe and Mail • 1d ago
Bank of America Builds 5.73% Stake in Qiagen via Shares and Derivatives The Globe and Mail report covering Qiagen N.V. (QGEN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
Qiagen (NYSE:QGEN) Stock Forecast & Analyst Predictions Simply Wall St report covering Qiagen N.V. (QGEN) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
QGEN Bull vs. Bear Conversation Board — What's Your Call at $50.22?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON QGEN 🐻 33% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH
🎯 Target: $59.40 (+18.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is QGEN (B- • RQD 71/100) a Buy at $50.34?
Welcome to the QGEN (Qiagen N.V.) Roar Pit. Current RQD Composite is 71/100 (Roarable Buy — Sound Institutional Accumulation) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $40.27 (-20.0%)
Spot @ $50.34 Pump the brakes on QGEN — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on QGEN, but look at what you are paying: 24.4x trailing P/E with 62.2% gross margins. Unless Qiagen N.V. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH
🎯 Target: $59.40 (+18.0%)
Spot @ $50.34 QGEN cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on QGEN, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $50.34 (52-wk range $32.53 - $57.82), any beat on forward guidance forces shorts and underweight funds to chase.